Figure 1

Prevalence of abnormal lipid and other cardiometabolic risk factors at baseline and 90 days following cART initiation in the DGPLEAD study. Comparing baseline measurements to those at 90 days following initiation of therapy, there was a significant change in the proportion of patients with low HDL-c (P<0.001), TC ≥5.18 mmol/L (P=0.03), TC:HDL-c ≥ 5.0 (P<0.001), HOMA-IR ≥3.0 (P<0.001) and BMI <18.5 (P<0.001). There was no significant change (P>0.05) in LDL-c ≥3.37 mmol/L, triglycerides ≥1.70 mmol/L and glucose ≥5.55 mmol/L. * Low HDL-c was defined as <1.04 mmol/L in men and <1.30 mmol/L in women. BMI, Body Mass Index; HDL-c, High Density Lipoprotein Cholesterol; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; LDL-c, Low Density Lipoprotein Cholesterol; TC, Total Cholesterol.